At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Norditropindrug
Likely dose
Norditropin 50 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Characterization and Trial of Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
Children's Hospital Medical Center, Cincinnati·interventional·Posted Sep 19, 2017·Updated Jul 30, 2024
In Brief
A Phase 2 clinical trial evaluating Norditropin for Short Stature. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This is an open-label, single-arm prospective pilot study to study the effects of a single dose regimen of daily growth hormone medication (Norditropin) on pre-pubertal children with Aggrecan deficiency. The growth response will be tracked over a 12 month period. A protocol extension has been approved to continue subjects on treatment for an additional 2 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShort Stature
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartFeb 2018
Primary CompletionMar 2023
Study CompletionAug 2023
TodayJul 2026
First PostedSep 19, 2017
Enrollment StartFeb 1, 2018
Primary CompletionMar 31, 2023
Study CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 8.8 years ago
Interventions
Norditropindrug
Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.